- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.07. | Nexalin Technology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.06. | Nexalin Technology, Inc.: Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS Platform | 1 | GlobeNewswire (USA) | ||
| NEXALIN TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 17.06. | Nexalin Technology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Nexalin Technology, Inc.: Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life ... | 240 | GlobeNewswire (Europe) | Study using Nexalin's proprietary DIFS 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results... ► Artikel lesen | |
| 10.06. | EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life | 2 | Benzinga.com | ||
| 04.06. | Nexalin receives U.S. patent for neurostimulation method | 1 | Investing.com | ||
| 04.06. | Nexalin erhält US-Patent für Neurostimulationsverfahren gegen Angst, Depression und Schlaflosigkeit | 1 | Investing.com Deutsch | ||
| 04.06. | Nexalin Technology, Inc.: Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia | 231 | GlobeNewswire (Europe) | Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurostimulation... ► Artikel lesen | |
| 27.05. | Nexalin Technology: EPS übertrifft Schätzungen - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 21.05. | Nexalin: $1.3 Million PONM Acquisition Expands AI-Integrated Neurostimulation Platform Ahead Of FDA Trial | 1 | pulse2.com | ||
| 21.05. | Nexalin Technology, Inc.: Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for ... | 3 | GlobeNewswire (USA) | ||
| 19.05. | Nexalin Technology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.05. | Nexalin Technology, Inc.: Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial | 483 | GlobeNewswire (Europe) | HOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NXL) ("Nexalin" or the "Company"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 08.05. | Nexalin Technology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.04. | Nexalin Technology, Inc.: Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia | 2 | GlobeNewswire (USA) | ||
| 22.04. | Nexalin Technology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Nexalin announces pivotal insomnia trial, targets Q2 enrollment | 1 | Investing.com | ||
| 22.04. | Nexalin Technology, Inc.: Nexalin Technology Advances Pivotal Clinical Trial of HALO Clarity Toward Q2 2026 Enrollment | 306 | GlobeNewswire (Europe) | HOUSTON, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 15.04. | Nexalin Technology, Inc.: Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China | 305 | GlobeNewswire (Europe) | HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 09.04. | Nexalin Technology, Inc.: Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CERENOME | 3,440 | +4,72 % | Cerenome subsidiary selects XiFin for diagnostic billing services | ||
| ORGANON | 11,700 | -0,59 % | Organon: $81 Million Jada Gain Lifts GAAP Profit 68% As Adjusted Earnings Fall 29% | ||
| QUIDELORTHO | 10,730 | +0,94 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| NANO-X IMAGING | 1,060 | 0,00 % | Nano-X Imaging prices $8M registered direct offering at $1 per share | ||
| ROCKWELL MEDICAL | 7,190 | +0,70 % | XFRA RWM: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILROCKWELL MEDICAL... ► Artikel lesen | |
| NUWELLIS, INC | 1,500 | +0,67 % | Nuwellis, Inc.: Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer | MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 20,390 | -0,10 % | Jefferies senkt Kursziel für Procept BioRobotics nach verfehlten Eingriffszahlen | ||
| NEURONETICS | 2,040 | -0,97 % | Neuronetics and Jorey Chernett Announce Shared Vision | ||
| PULSE BIOSCIENCES | 35,800 | -2,19 % | Pulse Biosciences targets early October enrollment completion for 164-patient NANOPULSE-AF study | ||
| OPTIMIZERX | 7,080 | 0,00 % | OptimizeRx Corporation: OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer | WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage... ► Artikel lesen | |
| ORTHOFIX MEDICAL | 8,900 | +2,30 % | Orthofix Medical Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PAVMED | 4,060 | -4,36 % | PAVmed Inc.: PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results | Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission
Lucid Diagnostics continued building... ► Artikel lesen | |
| OWLET | 5,520 | 0,00 % | Owlet Announces New $25 Million Credit Facility With Wells Fargo | ||
| QTREX QUANTUM | 1,050 | 0,00 % | QTREX Quantum Ltd. - 6-K, Report of foreign issuer | ||
| PICARD MEDICAL | 3,430 | 0,00 % | Picard Medical, Inc.: Picard Medical Receives NYSE American Acceptance of Compliance Plan | TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Company" or "Picard Medical"), parent company of SynCardia Systems LLC, maker of the world's first... ► Artikel lesen |
Das Unternehmen NEXALIN TECHNOLOGY INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,01 % bei einem Aktienkurs von 0,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXALIN TECHNOLOGY INC finden Sie auf Wallstreet Online.